CJC-1295
CJC-1295 (Modified GRF 1-29)
The GH amplifier
A 29-amino-acid growth hormone releasing hormone (GHRH) analog with enhanced stability. CJC-1295 extends the duration of natural GH pulses without disrupting pulsatile release patterns, providing sustained elevation of growth hormone and IGF-1 for recovery, body composition, and anti-aging.
Key Benefits
Sustained growth hormone elevation without disrupting pulsatility
Increased IGF-1 for muscle recovery and body composition
Improved deep sleep quality (GH pulses during slow-wave sleep)
Enhanced collagen synthesis for skin and connective tissue
Fat metabolism support through lipolysis activation
Mechanism of Action
How CJC-1295 works
CJC-1295 amplifies your natural growth hormone axis through GHRH receptor activation:
- GHRH receptor agonism — binds pituitary GHRH receptors with high affinity, stimulating somatotroph cells to synthesize and release growth hormone. Unlike exogenous GH, this preserves natural pulsatile release patterns
- Extended GH pulse duration — the modified amino acid sequence (tetrasubstituted residues at positions 2, 8, 15, 27) resists DPP-IV enzymatic degradation, extending each GH pulse from minutes to hours
- IGF-1 elevation — sustained GH pulses drive hepatic IGF-1 production, the downstream mediator responsible for muscle protein synthesis, collagen production, and cellular repair
- Somatostatin sensitivity preserved — unlike continuous GH infusion, CJC-1295 still responds to somatostatin feedback. When your body says "enough GH," the signal is respected, maintaining physiological safety
Your Genetics & CJC-1295
Genetic variants that affect your response
These SNPs determine how effectively CJC-1295 works for you specifically. A genetic peptide report identifies your variants before you start.
Variants in the GHRH receptor gene affect receptor density and binding affinity on pituitary somatotrophs. Reduced receptor expression means fewer targets for CJC-1295, potentially requiring dose adjustment to achieve equivalent GH elevation.
The GHR exon 3 deletion (d3-GHR) creates a shorter receptor with increased GH sensitivity. d3 carriers may achieve greater IGF-1 response from the same CJC-1295-induced GH pulse, potentially needing lower doses.
Promoter region variants affect baseline IGF-1 levels. Low-IGF1 genotypes may see more dramatic improvements from CJC-1295, while high-baseline carriers may need monitoring to avoid supraphysiological IGF-1.
SOCS2 is a negative regulator of GH signaling — it puts the brakes on the JAK/STAT pathway. Variants reducing SOCS2 function may amplify CJC-1295's downstream effects, increasing sensitivity to GH pulses.
Which variants do you carry?
Upload your DNA data or order a kit to find out.
Evidence & Research
30+
Published studies
Published human or robust animal studies with clear mechanistic rationale
Common Stacks
CJC-1295 is commonly combined with:
Frequently Asked Questions
What is CJC-1295 used for?
CJC-1295 is used to amplify natural growth hormone production for body composition, recovery, anti-aging, and sleep quality. It extends the duration of your natural GH pulses rather than replacing them, making it a physiologically conservative approach to GH optimization.
Why stack CJC-1295 with Ipamorelin?
CJC-1295 (GHRH analog) and Ipamorelin (ghrelin mimetic) work through different receptors. CJC-1295 amplifies pulse duration while Ipamorelin increases pulse amplitude. Together, they produce synergistic GH elevation — typically 2-3x more than either alone — while maintaining pulsatile release patterns.
Does genetics affect CJC-1295 response?
Yes. GHRHR variants affect how many receptor targets CJC-1295 has on your pituitary. The GHR d3 deletion determines downstream GH sensitivity. IGF1 promoter variants set your baseline, influencing how much room there is for improvement. A genetic peptide report maps these factors.
Learn More About CJC-1295
Personalize your protocol
Does CJC-1295 match your DNA?
Upload your existing genetic data or order a kit. Your report scores CJC-1295 against your unique genetic profile — CYP metabolism, receptor variants, pathway markers — in minutes.